Company
Official Name: Amgen Inc.
Headquarters: Thousand Oaks, CA, United States
Founded: April 8, 1980
Employees: 24,200
CEO: Mr. Robert A. Bradway
$176.43 Billion
USD as of Jan. 1, 2026
Amgen Inc. is a multinational biotechnology and pharmaceutical company. It produces various drugs, including Neulasta, which prevents infections for patients undergoing cancer chemotherapy, Enbrel, a necrosis blocker for the treatment of autoimmune diseases. Focusing on molecular biology and biochemistry, Amgen aims at developing health care through recombinant DNA technology.
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| AstraZeneca | $284.38 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | $35.97 B |
| EBITDA | $16.52 B |
| Gross Profit TTM | $25.20 B |
| Profit Margin | 19.47% |
| Operating Margin | 34.15% |
| Quarterly Revenue Growth | 12.40% |
Amgen Inc. has the following listings and related stock indices.
Stock: NASDAQ: AMGN wb_incandescent
Stock: FSX: AMG wb_incandescent
Stock: OTC: AMVMF wb_incandescent
Stock: XETR: AMG wb_incandescent
Aimovig, Aranesp, Blincyto, Epogen, Kineret, Enbrel, Kyprolis, Neulasta, Neupogen, Nplate, Parsabiv, Prolia, Repatha, Sensipar/Mimpara, Vectibix and Xgeva.
Robert A. Bradway (Chairman, President, & CEO)